Loss of Free Fatty Acid Receptor 2 leads to impaired islet mass and beta cell survival

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Villa, Stephanie R ^a   Priyadarshini, Medha ^a   Fuller, Miles H ^a   Bhardwaj, Tanya ^a   Brodsky, Michael R ^a   Angueira, Anthony R ^a   Mosser, Rockann E ^b   Carboneau, Bethany A ^b   Tersey, Sarah A ^c   Mancebo, Helena ^d   Gilchrist, Annette ^e   Mirmira, Raghavendra G ^c   Gannon, Maureen ^b,f   Layden, Brian T ^a,g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Multispan Inc   (United States)

^e MIDWESTERN UNIVERSITY   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

^g JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; FATTY ACID; FREE FATTY ACID 2 RECEPTOR, MOUSE; VOLATILE FATTY ACID;

ANIMAL; C57BL MOUSE; CELL CULTURE; CELL SURVIVAL; GENETICS; HUMAN; INSULIN RESISTANCE; KNOCKOUT MOUSE; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS; PANCREAS ISLET BETA CELL; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; FATTY ACIDS, VOLATILE; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PANCREAS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 84975789637     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28159     Document Type: Article

References (50)

1. Prentki, M. & Nolan, C. J. Islet beta cell failure in type 2 diabetes. The Journal of clinical investigation 116, 1802-1812, doi: 10.1172/JCI29103 (2006).
2. Meier, J. J. & Bonadonna, R. C. Role of reduced beta-cell mass versus impaired beta-cell function in the pathogenesis of type 2 diabetes. Diabetes care 36 Suppl 2, S113-119, doi: 10.2337/dcS13-2008 (2013).
3. Kendall, D. M., Sutherland, D. E., Najarian, J. S., Goetz, F. C. & Robertson, R. P. Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. The New England journal of medicine 322, 898-903, doi: 10.1056/NEJM199003293221305 (1990).
4. Menge, B. A. et al. Metabolic consequences of a 50% partial pancreatectomy in humans. Diabetologia 52, 306-317, doi: 10.1007/s00125-008-1219-1 (2009).
5. Butler, A. E. et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102-110 (2003).
6. Meier, J. J. Beta cell mass in diabetes: A realistic therapeutic target? Diabetologia 51, 703-713, doi: 10.1007/s00125-008-0936-9 (2008).
7. Freathy, R. M. et al. Type 2 diabetes risk alleles are associated with reduced size at birth. Diabetes 58, 1428-1433, doi: 10.2337/db08-1739 (2009).
8. Hattersley, A. T. & Tooke, J. E. The fetal insulin hypothesis: An alternative explanation of the association of low birthweight with diabetes and vascular disease. Lancet 353, 1789-1792, doi: 10.1016/S0140-6736(98)07546-1 (1999).
9. Garofano, A., Czernichow, P. & Breant, B. In utero undernutrition impairs rat beta-cell development. Diabetologia 40, 1231-1234, doi: 10.1007/s001250050812 (1997).
10. Breant, B., Gesina, E. & Blondeau, B. Nutrition, glucocorticoids and pancreas development. Hormone research 65 Suppl 3, 98-104, doi: 10.1159/000091513 (2006).
11. Nielsen, J. H. et al. Regulation of beta-cell mass by hormones and growth factors. Diabetes 50 Suppl 1, S25-29 (2001).
12. Oh, Y. S. Mechanistic insights into pancreatic beta-cell mass regulation by glucose and free fatty acids. Anatomy & cell biology 48, 16-24, doi: 10.5115/acb.2015.48.1.16 (2015).
13. Ahren, B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nature reviews. Drug discovery 8, 369-385, doi: 10.1038/nrd2782 (2009).
14. Guettier, J. M. et al. A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proceedings of the National Academy of Sciences of the United States of America 106, 19197-19202, doi: 10.1073/pnas.0906593106 (2009).
15. Jain, S. et al. Chronic activation of a designer G(q)-coupled receptor improves beta cell function. The Journal of clinical investigation 123, 1750-1762, doi: 10.1172/JCI66432 (2013).
16. Xu, G., Stoffers, D. A., Habener, J. F. & Bonner-Weir, S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48, 2270-2276 (1999).
17. Zhang, Y. et al. The role of G protein-coupled receptor 40 in lipoapoptosis in mouse beta-cell line NIT-1. Journal of molecular endocrinology 38, 651-661, doi: 10.1677/JME-06-0048 (2007).
18. Ruiz de Azua, I., Gautam, D., Guettier, J. M. & Wess, J. Novel insights into the function of beta-cell M3 muscarinic acetylcholine receptors: Therapeutic implications. Trends in endocrinology and metabolism: TEM 22, 74-80, doi: 10.1016/j.tem.2010.10.004 (2011).
19. Regard, J. B. et al. Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion. The Journal of clinical investigation 117, 4034-4043, doi: 10.1172/JCI32994 (2007).
20. Berger, M. et al. Galphai/o-coupled receptor signaling restricts pancreatic beta-cell expansion. Proceedings of the National Academy of Sciences of the United States of America 112, 2888-2893, doi: 10.1073/pnas.1319378112 (2015).
21. Kimple, M. E., Neuman, J. C., Linnemann, A. K. & Casey, P. J. Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes. Experimental & molecular medicine 46, e102, doi: 10.1038/emm.2014.40 (2014).
22. Ichimura, A., Hasegawa, S., Kasubuchi, M. & Kimura, I. Free fatty acid receptors as therapeutic targets for the treatment of diabetes. Frontiers in pharmacology 5, 236, doi: 10.3389/fphar.2014.00236 (2014).
23. Talukdar, S., Olefsky, J. M. & Osborn, O. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends in pharmacological sciences 32, 543-550, doi: 10.1016/j.tips.2011.04.004 (2011).
24. Keller, M. P. et al. A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome research 18, 706-716, doi: 10.1101/gr.074914.107 (2008).
25. Rieck, S. et al. The transcriptional response of the islet to pregnancy in mice. Molecular endocrinology 23, 1702-1712, doi: 10.1210/me.2009-0144 (2009).
26. Layden, B. T. et al. Regulation of pancreatic islet gene expression in mouse islets by pregnancy. The Journal of endocrinology 207, 265-279, doi: 10.1677/JOE-10-0298 (2010).
27. Layden, B. T., Angueira, A. R., Brodsky, M., Durai, V. & Lowe, W. L., Jr. Short chain fatty acids and their receptors: new metabolic targets. Translational research : The journal of laboratory and clinical medicine 161, 131-140, doi: 10.1016/j.trsl.2012.10.007 (2013).
28. Priyadarshini, M. et al. An acetate-specific GPCR, FFAR2, regulates insulin secretion. Molecular endocrinology, me20151007, doi: 10.1210/me.2015-1007 (2015).
29. McNelis, J. C. et al. GPR43 potentiates beta cell function in obesity. Diabetes, doi: 10.2337/db14-1938 (2015).
30. Tang, C. et al. Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. Nature medicine 21, 173-177, doi: 10.1038/nm.3779 (2015).
31. Weir, G. C. & Bonner-Weir, S. Islet beta cell mass in diabetes and how it relates to function, birth, and death. Ann N Y Acad Sci 1281, 92-105, doi: 10.1111/nyas.12031 (2013).
32. Fuller, M. et al. The short-chain fatty acid receptor, FFA2, contributes to gestational glucose homeostasis. American journal of physiology. Endocrinology and metabolism 309, E840-851, doi: 10.1152/ajpendo.00171.2015 (2015).
33. Winzell, M. S. & Ahren, B. G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes. Pharmacology & therapeutics 116, 437-448, doi: 10.1016/j.pharmthera.2007.08.002 (2007).
34. Fisher, M. M., Perez Chumbiauca, C. N., Mather, K. J., Mirmira, R. G. & Tersey, S. A. Detection of islet beta-cell death in vivo by multiplex PCR analysis of differentially methylated DNA. Endocrinology 154, 3476-3481, doi: 10.1210/en.2013-1223 (2013).
35. Akirav, E. M. et al. Detection of beta cell death in diabetes using differentially methylated circulating DNA. Proceedings of the National Academy of Sciences of the United States of America 108, 19018-19023, doi: 10.1073/pnas.1111008108 (2011).
36. Husseiny, M. I. et al. Development of a quantitative methylation-specific polymerase chain reaction method for monitoring beta cell death in type 1 diabetes. PloS one 7, e47942, doi: 10.1371/journal.pone.0047942 (2012).
37. Lebastchi, J. et al. Immune therapy and beta-cell death in type 1 diabetes. Diabetes 62, 1676-1680, doi: 10.2337/db12-1207 (2013).
38. Nielsen, J. H., Svensson, C., Galsgaard, E. D., Moldrup, A. & Billestrup, N. Beta cell proliferation and growth factors. Journal of molecular medicine 77, 62-66 (1999).
39. Huang, C., Snider, F. & Cross, J. C. Prolactin receptor is required for normal glucose homeostasis and modulation of beta-cell mass during pregnancy. Endocrinology 150, 1618-1626, doi: 10.1210/en.2008-1003 (2009).
40. Parsons, J. A., Brelje, T. C. & Sorenson, R. L. Adaptation of islets of Langerhans to pregnancy: increased islet cell proliferation and insulin secretion correlates with the onset of placental lactogen secretion. Endocrinology 130, 1459-1466, doi: 10.1210/endo.130.3.1537300 (1992).
41. Linnemann, A. K., Baan, M. & Davis, D. B. Pancreatic beta-cell proliferation in obesity. Advances in nutrition 5, 278-288, doi: 10.3945/an.113.005488 (2014).
42. Bjursell, M. et al. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. American journal of physiology. Endocrinology and metabolism 300, E211-220, doi: 10.1152/ajpendo.00229.2010 (2011).
43. Tolhurst, G. et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61, 364-371, doi: 10.2337/db11-1019 (2012).
44. Park, S., Jiang, H., Zhang, H. & Smith, R. G. Modification of ghrelin receptor signaling by somatostatin receptor-5 regulates insulin release. Proceedings of the National Academy of Sciences of the United States of America 109, 19003-19008, doi: 10.1073/pnas.1209590109 (2012).
45. Maudsley, S., Martin, B. & Luttrell, L. M. The origins of diversity and specificity in g protein-coupled receptor signaling. The Journal of pharmacology and experimental therapeutics 314, 485-494, doi: 10.1124/jpet.105.083121 (2005).
46. Asfari, M. et al. Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 130, 167-178, doi: 10.1210/endo.130.1.1370150 (1992).
47. Mosser, R. E. & Gannon, M. An assay for small scale screening of candidate beta cell proliferative factors using intact islets. BioTechniques 55, 310-312, doi: 10.2144/000114115 (2013).
48. Golson, M. L. et al. Activated FoxM1 attenuates streptozotocin-mediated beta-cell death. Molecular endocrinology 28, 1435-1447, doi: 10.1210/me.2014-1024 (2014).
49. Yamamoto, T. et al. Prolactin supplementation to culture medium improves beta-cell survival. Transplantation 89, 1328-1335, doi: 10.1097/TP.0b013e3181d98af1 (2010).
50. Whittle, B. J., Silverstein, A. M., Mottola, D. M. & Clapp, L. H. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist. Biochemical pharmacology 84, 68-75, doi: 10.1016/j.bcp.2012.03.012 (2012).